Polypill Versus Metformin in New Onset Type 2 Diabetes
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- George Medicines PTY Limited
- Target Recruit Count
- 334
- Registration Number
- NCT05833958
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Phase 3
Completed
- Conditions
- Interventions
- Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mgDrug: Telmisartan 20 mg/amlodipine 2.5 mg .Drug: Amlodipine 2.5 mg/indapamide 1.25 mgDrug: Telmisartan 20 mg/indapamide 1.25 mgDrug: telmisartan 40 mg/amlodipine 5 mgDrug: telmisartan 40 mg/indapamide 2.5 mgDrug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mgDrug: amlodipine 5 mg/indapamide 2.5 mg
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- George Medicines PTY Limited
- Target Recruit Count
- 1385
- Registration Number
- NCT04518293
- Locations
- 🇦🇺
Curtin University, Bentley, Western Australia, Australia
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇱🇰Karapitiya Teaching Hospital, Galle, Sri Lanka
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- George Medicines PTY Limited
- Target Recruit Count
- 295
- Registration Number
- NCT04518306
- Locations
- 🇺🇸
Buckhead Primary Care Research, Snellville, Georgia, United States
🇺🇸Valiance Clinical Research, Tarzana, California, United States
🇬🇧Albany House Medical Centre, Wellingborough, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath